Cargando…
Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
Tamoxifen is a drug that is often used in the clinical management of breast cancer. CYP2D6 is a key metabolizing enzyme that is involved in the conversion of tamoxifen to its active drug metabolites. CYP2D6 has several alleles that metabolize tamoxifen and other drugs at different rates that can alt...
Autores principales: | Reis, Sara S., Carvalho, Ana S., Fernandes, Rúben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681270/ https://www.ncbi.nlm.nih.gov/pubmed/31284530 http://dx.doi.org/10.3390/medicina55070344 |
Ejemplares similares
-
CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010) -
CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
por: Damkier, Per, et al.
Publicado: (2017) -
Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
por: Wigle, Theodore J., et al.
Publicado: (2017) -
CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005) -
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)